Waters (NYSE:WAT) Given New $360.00 Price Target at Barclays

Waters (NYSE:WAT) had its price objective raised by Barclays from $330.00 to $360.00 in a research note released on Monday, Benzinga reports. Barclays currently has an underweight rating on the medical instruments supplier’s stock.

Several other research firms also recently commented on WAT. Leerink Partners upgraded Waters from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $325.00 to $375.00 in a research note on Thursday, August 1st. Evercore ISI upped their price target on Waters from $335.00 to $355.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Leerink Partnrs raised Waters from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 1st. Jefferies Financial Group upgraded Waters from a “hold” rating to a “buy” rating and boosted their price objective for the company from $355.00 to $415.00 in a research note on Tuesday, October 8th. Finally, Cfra set a $389.00 target price on shares of Waters in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $365.85.

Waters Trading Down 0.1 %

Shares of Waters stock opened at $386.59 on Monday. The stock has a fifty day moving average price of $344.06 and a 200-day moving average price of $326.73. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.02 and a quick ratio of 0.55. The firm has a market cap of $22.96 billion, a PE ratio of 36.90, a P/E/G ratio of 7.50 and a beta of 0.97. Waters has a 1 year low of $241.95 and a 1 year high of $393.38.

Waters (NYSE:WAT) last posted its quarterly earnings data on Friday, November 1st. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.25. The business had revenue of $740.30 million during the quarter, compared to the consensus estimate of $712.99 million. Waters had a net margin of 21.43% and a return on equity of 49.93%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 earnings per share. Equities research analysts anticipate that Waters will post 11.67 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Itau Unibanco Holding S.A. bought a new stake in Waters during the second quarter valued at $33,000. Kennebec Savings Bank purchased a new stake in shares of Waters in the 3rd quarter valued at about $33,000. Blue Trust Inc. boosted its position in shares of Waters by 190.2% during the 2nd quarter. Blue Trust Inc. now owns 119 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 78 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Waters during the third quarter worth about $35,000. Finally, TFC Financial Management Inc. increased its position in shares of Waters by 19,900.0% in the second quarter. TFC Financial Management Inc. now owns 200 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 199 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.